Home > Publications > Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma.
Centenary Institute - Medical Research
Centenary Institute - Medical Research

Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma.

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP and Ribas A.

New England Journal of Medicine. 369(2):134-144 2013.

Date: 2013

//